13F-HR filed by Abingworth LLP
Abingworth LLP filed this 13F-HR for the quarter ended 2021-06-30, filed 2021-08-16, with 19 holding rows worth $323,501,000.
- Accession
- 0000950123-21-011049
- Filer
- CIK 1397144
- Filed
- 2021-08-16
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q2 2021
A holdings report, 19 entries on the cover page, a total value of $323,501,000 stated on the cover page (in dollars after the unit check, H1), rows summing to $323,501,000 with VALUE read as thousands by filing date, 13F file number 028-14285. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| VAXCYTE INC COM | 92243G108 | Stock | 4,168,718 | $93,629,000 | thousands by filing date | |
| PHATHOM PHARMACEUTICALS INC | 71722W107 | COMMON STOCK | 1,203,135 | $40,726,000 | thousands by filing date | |
| VERA THERAPEUTICS INC | 92337R101 | COMMON STOCK | 2,960,231 | $38,513,000 | thousands by filing date | |
| Spruce Bio | E5209E109 | Common | 1,792,518 | $20,076,000 | thousands by filing date | |
| SIENTRA INC | 82621J105 | COM | 2,390,843 | $19,031,000 | thousands by filing date | |
| RENEO PHARMACEUTICALS INC | 75974E103 | COM | 1,962,221 | $18,190,000 | thousands by filing date | |
| SIERRA ONCOLOGY INC | 82640U107 | COM | 871,125 | $16,813,000 | thousands by filing date | |
| ADICET BIO INC | 007002108 | COM | 1,615,385 | $16,574,000 | thousands by filing date | |
| VERONA PHARMA PLC | 925050106 | SPONSORED ADS | 2,457,499 | $15,998,000 | thousands by filing date | |
| SOLENO THERAPEUTIVS, INC. | 834203200 | COMM | 10,302,602 | $11,642,000 | thousands by filing date | |
| EXICURE INC | 30205M101 | COM | 6,977,000 | $10,396,000 | thousands by filing date | |
| NUCANA PLC | 67022C106 | ADR | 3,333,333 | $9,200,000 | thousands by filing date | |
| PARATEK PHARMACEUTICALS INC | 699374302 | Equity | 1,041,131 | $7,090,000 | thousands by filing date | |
| AEGLEA BIOTHERAPEUTICS INC | 00773J103 | COM | 240,500 | $1,671,000 | thousands by filing date | |
| MOLECULAR TEMPLATES INC | 608550109 | COM | 200,000 | $1,564,000 | thousands by filing date | |
| X4 Pharmaceuticals, Inc. | 98420X103 | COM | 229,885 | $1,494,000 | thousands by filing date | |
| CYMABAY THERAPEUTICS INC | 23257D103 | COM | 131,036 | $571,000 | thousands by filing date | |
| ObsEva SA | H5861P103 | COM | 87,999 | $266,000 | thousands by filing date | |
| Ocugen | 43358V109 | Common | 7,111 | $57,000 | thousands by filing date |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000950123-21-011049 | this filing | 2021-08-16 | acceptance time not in the bulk data set |